ArticleMolecules (Basel, Switzerland)2020
Harringtonine Inhibits Zika Virus Infection through Multiple Mechanisms.
Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Structure-Guided Repurposing of Approved Drugs Identifies Aprepitant and Mavorixafor as Putative δ-Opioid Receptor Agonist Candidates.International journal of molecular sciences · 2026Article
- Natural Alkaloids as Antiviral Agents Against RNA Viruses: A Comprehensive and Mechanistic Review.Molecules (Basel, Switzerland) · 2026Review
- Novel and repurposed antiviral molecules for arbovirus infections with epidemic Potential: A systematic review.New microbes and new infections · 2025Review
- Dengue and Flavivirus Co-Infections: Challenges in Diagnosis, Treatment, and Disease Management.International journal of molecular sciences · 2025Review
- Review
- Sulfur/selenium-functionalized benzotriazoles as multifunctional antivirals targeting Zika & Chikungunya.Future medicinal chemistry · 2025Article
- Molecular insights into the inhibition mechanism of harringtonine against essential proteins associated with SARS-CoV-2 entry.International journal of biological macromolecules · 2023Article
- Natural Products and Derivatives as PotentialViruses · 2023Review
- Fangchinoline inhibits the PEDV replication in intestinal epithelial cells via autophagic flux suppression.Frontiers in microbiology · 2023Article
- Novel Therapeutic Nutrients Molecules That Protect against Zika Virus Infection with a Special Note on Palmitoleate.Nutrients · 2022Review
- Clinical Management of Herpes Simplex Virus Keratitis.Diagnostics (Basel, Switzerland) · 2022Review
- Indole alkaloids inhibit zika and chikungunya virus infection in different cell lines.BMC complementary medicine and therapies · 2021Article
- Micafungin Inhibits Dengue Virus Infection through the Disruption of Virus Binding, Entry, and Stability.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Harringtonine Inhibits Herpes Simplex Virus Type 1 Infection by Reducing Herpes Virus Entry Mediator Expression.Frontiers in microbiology · 2021Article
- Arthropod-Borne Disease Control at a Glance: What's New on Drug Development?Molecules (Basel, Switzerland) · 2020Article
- Overcoming Resistance: A Comprehensive Review and Treatment Approach for Acyclovir-Resistant Herpes Simplex Keratitis.Journal of current ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Mosquito-borne Zika virus (ZIKV) is a Flavivirus that came under intense study from 2014 to 2016 for its well-known ability to cause congenital microcephaly in fetuses and neurological Guillain-Barré disease in adults. Substantial research on screening antiviral agents against ZIKV and preventing ZIKV infection are globally underway, but Food and Drug Administration (FDA)-approved treatments are not available yet. Compounds from Chinese medicinal herbs may offer an opportunity for potential therapies for anti-ZIKV infection. In this study, we evaluated the antiviral efficacy of harringtonine against ZIKV. Harringtonine possessed anti-ZIKV properties against the binding, entry, replication, and release stage through the virus life cycle. In addition, harringtonine have strong virucidal effects in ZIKV and exhibited prophylaxis antiviral ability prior ZIKV infection. The antiviral activity also observed in the treatment against Japanese encephalitis reporter virus (RP9-GFP strain). Overall, this study demonstrated that harringtonine would be a favorable potential candidate for the development of anti-ZIKV infection therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.